<DOC>
	<DOC>NCT01733823</DOC>
	<brief_summary>P16 negative cancers continue to have a dismal prognosis despite advances in the treatment of head and neck cancer. Acceleration, dose-escalation, hyperfractionation, chemotherapy and nimorazole has been shown to improve local control. The purpose of the study i to investigate the level of co-morbidity and performance status (PS) that allows the combination of all of the above means of treatment intensification</brief_summary>
	<brief_title>DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Nimorazole</mesh_term>
	<criteria>Squamous Cell Carcinoma head and neck cancer of the pharynx, larynx and oral cavity P16 negative T14 N13 M0 Organ function and performance status allowing radical chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>